A gastrin-releasing peptide receptor antagonist blocks d-amphetamine-induced hyperlocomotion and increases hippocampal NGF and BDNF levels in rats

Peptides

Volumn 28, Issue 7, 2007, Pages 1447-1452

  Kauer Sant'Anna, Márcia ^a   Andreazza, Ana Cristina ^a   Valvassori, Samira S ^b   Martins, Márcio Rodrigo ^b   Barbosa, Luciana M ^b   Schwartsmann, Gilberto ^c   Roesler, Rafael ^c   Quevedo, João ^b   Kapczinski, Flávio ^a  

^a Academic Hospital Research Center   (Brazil)

^b UNIVERSITY OF SOUTHERN SANTA CATARINA   (Brazil)

^c FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

Author keywords

BDNF; Bipolar disorder; Bombesin like peptides; Gastrin releasing peptide receptor; NGF; RC 3095

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; DEXAMPHETAMINE; GASTRIN RELEASING PEPTIDE RECEPTOR; NERVE GROWTH FACTOR; RC 3095;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIPOLAR DISORDER; CONTROLLED STUDY; DRUG ACTIVITY; DRUG DOSE COMPARISON; DRUG EFFECT; HIPPOCAMPUS; LOCOMOTION; MALE; MANIA; NEUROPHARMACOLOGY; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; BIPOLAR DISORDER; BOMBESIN; BRAIN-DERIVED NEUROTROPHIC FACTOR; DEXTROAMPHETAMINE; HIPPOCAMPUS; MALE; MOTOR ACTIVITY; NERVE GROWTH FACTOR; PEPTIDE FRAGMENTS; RATS; RATS, WISTAR; RECEPTORS, BOMBESIN;

ANIMALIA; RATTUS;

EID: 34547110146     PISSN: 01969781     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.peptides.2007.06.010     Document Type: Article

References (40)

1. Belmaker R.H. Bipolar disorder. N Engl J Med 351 (2004) 476-486
2. Bramham C.R., and Messaoudi E. BDNF function in adult synaptic plasticity: the synaptic consolidation hypothesis. Prog Neurobiol 76 (2005) 99-125
3. Chao M.V., Rajagopal R., and Lee F.S. Neurotrophin signalling in health and disease. Clin Sci 110 (2006) 167-173
4. Chen M.J., Nguyen T.V., Pike C.J., and Russo-Neustadt A.A. Norepinephrine induces BDNF and activates the PI-3K and MAPK cascades in embryonic hippocampal neurons. Cell Signal 19 (2007) 114-128
5. Cunha A.B., Frey B.N., Andreazza A.C., Goi J.D., Rosa A.R., Goncalves C.A., et al. Serum brain-derived neurotrophic factor is decreased in bipolar disorder during depressive and manic episodes. Neurosci Lett 398 (2006) 215-219
6. Dantas A.S., Luft T., Henriques J.A., Schwartsmann G., and Roesler R. Opposite effects of low and high doses of the gastrin-releasing peptide receptor antagonist RC-3095 on memory consolidation in the hippocampus: possible involvement of the GABAergic system. Peptides 27 (2006) 2307-2312
7. Frey B.N., Andreazza A.C., Cereser K.M., Martins M.R., Petronilho F.C., de Souza D.F., et al. Evidence of astrogliosis in rat hippocampus after d-amphetamine exposure. Prog Neuropsychopharmacol Biol Psychiatry 30 (2006) 1231-1234
8. Frey B.N., Andreazza A.C., Cereser K.M., Martins M.R., Valvassori S.S., Reus G.Z., et al. Effects of mood stabilizers on hippocampus BDNF levels in an animal model of mania. Life Sci 79 (2006) 281-286
9. Frey B.N., Martins M.R., Petronilho F.C., Dal-Pizzol F., Quevedo J., and Kapczinski F. Increased oxidative stress after repeated amphetamine exposure: possible relevance as a model of mania. Bipolar Disord 8 (2006) 275-280
10. Frey B.N., Valvassori S.S., Gomes K.M., Martins M.R., Dal-Pizzol F., Kapczinski F., et al. Increased oxidative stress in submitochondrial particles after chronic amphetamine exposure. Brain Res 1097 (2006) 224-229
11. Frey B.N., Valvassori S.S., Reus G.Z., Martins M.R., Petronilho F.C., Bardini K., et al. Changes in antioxidant defense enzymes after d-amphetamine exposure: implications as an animal model of mania. Neurochem Res 31 (2006) 699-703
12. Frey B.N., Valvassori S.S., Reus G.Z., Martins M.R., Petronilho F.C., Bardini K., et al. Effects of lithium and valproate on amphetamine-induced oxidative stress generation in an animal model of mania. J Psychiatry Neurosci 31 (2006) 326-332
13. Friedman W.J., Altiok N., Fredholm B.B., and Persson H. Mechanisms of nerve growth factor mRNA regulation by interleukin-1 beta in hippocampal cultures: role of second messengers. J Neurosci Res 33 (1992) 37-46
14. Hefti F., and Weiner W.J. Nerve growth factor and Alzheimer's disease. Ann Neurol 20 (1986) 275-281
15. Hellweg R., and Jockers-Scherubl M. Neurotrophic factors in memory disorders. Life Sci 55 (1994) 2165-2169
16. Luft T., Flores D.G., Vianna M.R., Schwartsmann G., Roesler R., and Izquierdo I. A role for hippocampal gastrin-releasing peptide receptors in extinction of aversive memory. Neuroreport 17 (2006) 935-939
17. Machado-Vieira R., Dietrich M.O., Leke R., Cereser V.H., Zanatto V., Kapczinski F., et al. Decreased plasma brain derived neurotrophic factor levels in unmedicated bipolar patients during manic episode. Biol Psychiatry 61 (2007) 142-144
18. Machado-Vieira R., Kapczinski F., and Soares J.C. Perspectives for the development of animal models of bipolar disorder. Prog Neuropsychopharmacol Biol Psychiatry 28 (2004) 209-224
19. Manji H.K., Quiroz J.A., Payne J.L., Singh J., Lopes B.P., Viegas J.S., et al. The underlying neurobiology of bipolar disorder. World Psychiatry 2 (2003) 136-146
20. Martins M.R., Reinke A., Valvassori S.S., Machado R.A., Quevedo J., Schwartsmann G., et al. Non-associative learning and anxiety in rats treated with a single systemic administration of the gastrin-releasing peptide receptor antagonist RC-3095. Peptides 26 (2005) 2525-2529
21. Meller C.A., Henriques J.A., Schwartsmann G., and Roesler R. The bombesin/gastrin releasing peptide receptor antagonist RC-3095 blocks apomorphine but not MK-801-induced stereotypy in mice. Peptides 25 (2004) 585-588
22. Merali Z., and Piggins H. Effects of dopamine D1 and D2 receptor agonists and antagonists on bombesin-induced behaviors. Eur J Pharmacol 191 (1990) 281-293
23. Moody T.W., and Merali Z. Bombesin-like peptides and associated receptors within the brain: distribution and behavioral implications. Peptides 25 (2004) 511-520
24. Mountney C., Sillberg V., Kent P., Anisman H., and Merali Z. The role of gastrin-releasing peptide on conditioned fear: differential cortical and amygdaloid responses in the rat. Psychopharmacology 189 (2006) 287-296
25. Obata K., Yamanaka H., Dai Y., Tachibana T., Fukuoka T., Tokunaga A., et al. Differential activation of extracellular signal-regulated protein kinase in primary afferent neurons regulates brain-derived neurotrophic factor expression after peripheral inflammation and nerve injury. J Neurosci 23 (2003) 4117-4126
26. Obrietan K., Gao X.B., and Van Den Pol A.N. Excitatory actions of GABA increase BDNF expression via a MAPK-CREB-dependent mechanism-a positive feedback circuit in developing neurons. J Neurophysiol 88 (2002) 1005-1015
27. Ohki-Hamazaki H., Iwabuchi M., and Maekawa F. Development and function of bombesin-like peptides and their receptors. Int J Dev Biol 49 (2005) 293-300
28. Olson L. NGF and the treatment of Alzheimer's disease. Exp Neurol 124 (1993) 5-15
29. Piggins H., and Merali Z. The effects of concurrent D-1 and D-2 dopamine receptor blockade with SCH 23390 and eticlopride, on bombesin-induced behaviours. Prog Neuropsychopharmacol Biol Psychiatry 13 (1989) 583-594
30. Rao J.S., Ertley R.N., Lee H.J., Demar Jr. J.C., Arnold J.T., Rapoport S.I., et al. n-3 Polyunsaturated fatty acid deprivation in rats decreases frontal cortex BDNF via a p38 MAPK-dependent mechanism. Mol Psychiatry 12 (2007) 36-46
31. Roesler R., Henriques J.A.P., and Schwartsmann G. Gastrin-releasing peptide receptor as a molecular target for psychiatric and neurological disorders. CNS Neurol Disord Drug Targets 5 (2006) 197-204
32. Roesler R., Henriques J.A.P., and Schwartsmann G. Neuropeptides and anxiety disorders: bombesin receptors as novel therapeutic targets. Trends Pharmacol Sci 25 (2004) 241-242
33. Roesler R., Luft T., Oliveira S.H., Farias C.B., Almeida V.R., Quevedo J., et al. Molecular mechanisms mediating gastrin-releasing peptide receptor modulation of memory consolidation in the hippocampus. Neuropharmacology 51 (2006) 350-357
34. Roesler R., Kopschina M.I., Rosa R.M., Henriques J.A., Souza D.O., and Schwartsmann G. RC-3095, a bombesin/gastrin-releasing peptide antagonist, impairs aversive but not recognition memory in rats. Eur J Pharmacol 486 (2004) 35-41
35. Roesler R., Lessa D., Venturella R., Vianna M.R., Luft T., Henriques J.A., et al. Bombesin/gastrin-releasing peptide receptors in the basolateral amygdala regulate memory consolidation. Eur J Neurosci 19 (2004) 1041-1045
36. Roesler R., Meller C.A., Kopschina M.I., Souza D.O., Henriques J.A., and Schwartsmann G. Intrahippocampal infusion of the bombesin/gastrin-releasing peptide antagonist RC-3095 impairs inhibitory avoidance retention. Peptides 24 (2003) 1069-1074
37. Shaltiel G, Chen G, Manji HK. Neurotrophic signaling cascades in the pathophysiology and treatment of bipolar disorder. Curr Opin Pharmacol 2006;Oct 18: [Epub ahead of print].
38. Strakowski S.M., Delbello M.P., and Adler C.M. The functional neuroanatomy of bipolar disorder: a review of neuroimaging findings. Mol Psychiatry 10 (2005) 105-116
39. Vawter M.P., Freed W.J., and Kleinman J.E. Neuropathology of bipolar disorder. Biol Psychiatry 48 (2000) 486-504
40. Yildiz-Yesiloglu A., and Ankerst D.P. Neurochemical alterations of the brain in bipolar disorder and their implications for pathophysiology: a systematic review of the in vivo proton magnetic resonance spectroscopy findings. Prog Neuropsychopharmacol Biol Psychiatry 30 (2006) 969-995